Nurix Therapeutics, Inc. (NRIX)
Largest Insider Buys in Sector
NRIX Stock Price History Chart
NRIX Stock Performance
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Insider Activity of Nurix Therapeutics, Inc.
Over the last 12 months, insiders at Nurix Therapeutics, Inc. have bought $0 and sold $925,402 worth of Nurix Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Nurix Therapeutics, Inc. have bought $0 and sold $2.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Nurix Therapeutics, Inc.
| 2024-06-20 | Sale | van Houte Hans | Chief Financial Officer | 20,000 0.0418% | $20.01 | $400,216 | +0.29% | |
| 2024-06-13 | Sale | Ring Christine | Chief Legal Officer | 1,864 0.0033% | $17.02 | $31,721 | +24.33% | |
| 2024-06-12 | Sale | Ring Christine | Chief Legal Officer | 1,900 0.0034% | $17.01 | $32,319 | +18.91% | |
| 2024-06-05 | Sale | Ring Christine | Chief Legal Officer | 400 0.0007% | $17.00 | $6,801 | -2.08% | |
| 2024-06-03 | Sale | Ring Christine | Chief Legal Officer | 1,596 0.0029% | $17.01 | $27,153 | +2.61% | |
| 2024-05-02 | Sale | van Houte Hans | Chief Financial Officer | 3,499 0.0059% | $12.83 | $44,878 | +23.45% | |
| 2024-04-30 | Sale | van Houte Hans | Chief Financial Officer | 1,387 0.0023% | $12.04 | $16,703 | +30.17% | |
| 2024-04-30 | Sale | Hansen Gwenn | Chief Scientific Officer | 2,007 0.0034% | $12.04 | $24,169 | +30.17% | |
| 2024-04-30 | Sale | Ring Christine | Chief Legal Officer | 1,513 0.0026% | $12.04 | $18,220 | +30.17% | |
| 2024-02-16 | Sale | van Houte Hans | Chief Financial Officer | 6,812 0.0143% | $10.02 | $68,223 | +46.50% | |
| 2024-01-30 | Sale | van Houte Hans | Chief Financial Officer | 1,671 0.0034% | $7.99 | $13,352 | +76.44% | |
| 2024-01-30 | Sale | Hansen Gwenn | Chief Scientific Officer | 2,334 0.0048% | $7.99 | $18,649 | +76.44% | |
| 2024-01-30 | Sale | Ring Christine | Chief Legal Officer | 1,760 0.0036% | $7.99 | $14,063 | +76.44% | |
| 2023-12-20 | Sale | van Houte Hans | Chief Financial Officer | 3,541 0.0074% | $10.00 | $35,421 | +35.41% | |
| 2023-12-19 | Sale | van Houte Hans | Chief Financial Officer | 10,906 0.0228% | $10.00 | $109,093 | +35.74% | |
| 2023-10-31 | Sale | van Houte Hans | Chief Financial Officer | 1,080 0.0021% | $5.20 | $5,613 | +113.86% | |
| 2023-10-31 | Sale | Hansen Gwenn | Chief Scientific Officer | 1,633 0.0031% | $5.20 | $8,487 | +113.86% | |
| 2023-10-31 | Sale | Ring Christine | Chief Legal Officer | 1,232 0.0024% | $5.20 | $6,403 | +113.86% | |
| 2023-07-31 | Sale | van Houte Hans | Chief Financial Officer | 1,245 0.0023% | $9.65 | $12,020 | -4.22% | |
| 2023-07-31 | Sale | Hansen Gwenn | Chief Scientific Officer | 1,884 0.0035% | $9.65 | $18,189 | -4.22% |
Institutional Investor Ownership
| BlackRock | $67.33M | 7.72 | 4.58M | -1.36% | -$930,833.40 | <0.01 | |
| Redmile Group | $65.9M | 7.56 | 4.48M | +37.66% | +$18.03M | 2.44 | |
| Baker Bros Advisors LP | $57.07M | 6.55 | 3.88M | 0% | +$0 | 0.72 | |
| Deep Track Capital Lp | $44.07M | 5.06 | 3M | 0% | +$0 | 0.2 | |
| State Street | $40.12M | 4.6 | 2.73M | +196.24% | +$26.58M | <0.01 | |
| ARK Investment Management LLC | $38.74M | 4.44 | 2.64M | -17.52% | -$8.23M | 0.27 | |
| The Vanguard Group | $37.99M | 4.36 | 2.58M | -0.53% | -$202,815.90 | <0.01 | |
| Morgan Stanley | $37.2M | 4.27 | 2.53M | -19.27% | -$8.88M | <0.01 | |
| T. Rowe Price | $32.28M | 3.7 | 2.2M | -8.11% | -$2.85M | <0.01 | |
| Deutsche Bank | $22.04M | 2.53 | 1.5M | +197.37% | +$14.63M | 0.01 | |
| Wasatch Advisors | $18.18M | 2.09 | 1.24M | -55.02% | -$22.24M | 0.1 | |
| Bain Capital Life Sciences Investors Llc | $16.65M | 1.91 | 1.13M | -37.88% | -$10.15M | 1.67 | |
| Soleus Capital Management, L.P. | $16.39M | 1.88 | 1.11M | +679.72% | +$14.29M | 0.16 | |
| Geode Capital Management | $16.18M | 1.86 | 1.1M | +1.83% | +$291,274.02 | <0.01 | |
| Dimensional Fund Advisors | $14.21M | 1.63 | 966,453 | -3.36% | -$493,787.70 | <0.01 | |
| Candriam S C A | $13.11M | 1.5 | 892,110 | -2.83% | -$382,200.00 | 0.08 | |
| Affinity Asset Advisors | $11.91M | 1.37 | 810,253 | +17.41% | +$1.77M | 2.12 | |
| Charles Schwab | $9.44M | 1.08 | 642,190 | +3.2% | +$292,427.10 | <0.01 | |
| Goldman Sachs | $7.24M | 0.83 | 492,666 | +74.77% | +$3.1M | <0.01 | |
| Jacobs Levy Equity Management | $6.39M | 0.73 | 434,413 | +73.54% | +$2.71M | 0.03 | |
| Nuveen | $6.16M | 0.71 | 418,823 | -21.55% | -$1.69M | <0.01 | |
| Northern Trust | $5.94M | 0.68 | 404,010 | -3.07% | -$188,218.80 | <0.01 | |
| Millennium Management LLC | $5.5M | 0.63 | 374,249 | -0.88% | -$49,083.30 | <0.01 | |
| Bessemer Group Inc | $5.25M | 0.6 | 357,287 | 0% | +$0 | 0.01 | |
| Arrowmark Colorado Holdings Llc | $4.63M | 0.53 | 314,762 | 0% | +$0 | 0.01 | |
| Invesco | $4.6M | 0.53 | 312,910 | +515.66% | +$3.85M | <0.01 | |
| Ikarian Capital LLC | $4.41M | 0.51 | 300,000 | New | +$4.41M | 1.26 | |
| Taddei Ludwig Associates Inc | $4.16M | 0.48 | 283,333 | 0% | +$0 | 1.05 | |
| PRIMECAP Management Co | $4.1M | 0.47 | 279,000 | New | +$4.1M | <0.01 | |
| Schonfeld Group | $3.85M | 0.44 | 262,162 | New | +$3.85M | 0.03 | |
| Parkman Healthcare Partners Llc | $3.67M | 0.42 | 250,000 | New | +$3.67M | 0.45 | |
| Connor Clark & Lunn Investment Management Ltd | $3.49M | 0.4 | 237,104 | +28.12% | +$764,899.84 | 0.01 | |
| Wellington Management Company | $3.43M | 0.39 | 233,136 | +13.54% | +$408,836.38 | <0.01 | |
| Citadel Advisors LLC | $3.16M | 0.36 | 214,716 | +573.75% | +$2.69M | <0.01 | |
| Trexquant Investment LP | $3.13M | 0.36 | 212,879 | +33.62% | +$787,346.62 | 0.04 | |
| Rafferty Asset Management Llc | $3.11M | 0.36 | 211,425 | New | +$3.11M | 0.01 | |
| Two Sigma | $3.11M | 0.36 | 211,316 | +122.97% | +$1.71M | 0.01 | |
| Arrowstreet Capital, Limited Partnership | $2.76M | 0.32 | 187,743 | -3.79% | -$108,684.10 | <0.01 | |
| Citigroup | $2.72M | 0.31 | 184,780 | +1,120.07% | +$2.49M | <0.01 | |
| Renaissance Technologies | $2.64M | 0.3 | 179,300 | +55.64% | +$942,373.68 | <0.01 | |
| Two Sigma Advisers LP | $2.62M | 0.3 | 177,900 | +511.34% | +$2.19M | <0.01 | |
| UBS | $2.48M | 0.29 | 168,942 | +121.12% | +$1.36M | <0.01 | |
| ExodusPoint Capital Management, LP | $2.43M | 0.28 | 165,603 | -44.38% | -$1.94M | 0.03 | |
| Acadian Asset Management | $2.35M | 0.27 | 160,293 | +576.71% | +$2.01M | 0.01 | |
| BNY Mellon | $2.34M | 0.27 | 159,218 | -8.01% | -$203,727.33 | <0.0001 | |
| Massachusetts Financial Services Co Ma | $1.66M | 0.19 | 112,779 | -20.66% | -$431,694.82 | <0.0001 | |
| Ameriprise Financial | $1.56M | 0.18 | 105,864 | -4.38% | -$71,265.56 | <0.0001 | |
| Los Angeles Capital Management LLC | $1.5M | 0.17 | 102,321 | -18.79% | -$348,096.07 | 0.01 | |
| Bank of America | $1.43M | 0.16 | 97,176 | +413.18% | +$1.15M | <0.0001 | |
| Jasper Ridge Partners, L.P. | $1.41M | 0.16 | 95,711 | 0% | +$0 | 0.04 |